Cobimetinib demonstrates significant clinical benefits in BRAF-mutant melanoma and histiocytic neoplasms.

Clinical Outcomes in Target Populations

In melanoma (Trial 1), cobimetinib + vemurafenib improved median progression-free survival (12.3 vs. 7.2 months; HR 0.56) and overall survival (22.3 vs. 17.4 months; HR 0.69) versus vemurafenib alone. Objective response rate (ORR) was 70% (16% complete responses). For histiocytic neoplasms (Trial 2), cobimetinib monotherapy achieved a 76.9% PET-based ORR (61.5% complete responses) and 46.2% RECIST-based ORR. Efficacy was observed across BRAF V600E/K and wild-type subtypes. Median duration of response exceeded 13 months in melanoma and 31 months in histiocytosis. Subgroup analyses supported consistent benefits in BRAF mutation variants.